Victory Capital Management Inc Fate Therapeutics Inc Transaction History

Victory Capital Management Inc

  • $98.4 Billion
  • Q1 2024

A detailed history of Victory Capital Management Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 183,950 shares of FATE stock, worth $603,356. This represents 0.0% of its overall portfolio holdings.

Number of Shares
183,950
Previous 12,504 1371.13%
Holding current value
$603,356
Previous $46,000 2834.78%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024
BUY
$3.54 - $8.35 $606,918 - $1.43 Million
171,446 Added 1371.13%
183,950 $1.35 Million
Q4 2023

Feb 05, 2024
BUY
$1.65 - $3.94 $3,831 - $9,148
2,322 Added 22.8%
12,504 $46,000
Q3 2023

Nov 06, 2023
BUY
$2.02 - $5.04 $20,567 - $51,317
10,182 New
10,182 $21,000
Q1 2023

May 02, 2023
SELL
$4.24 - $11.12 $3.18 Million - $8.34 Million
-749,574 Reduced 98.65%
10,228 $58,000
Q4 2022

Feb 09, 2023
SELL
$9.86 - $23.83 $2.18 Million - $5.27 Million
-221,137 Reduced 22.54%
759,802 $7.67 Million
Q3 2022

Nov 02, 2022
SELL
$21.04 - $36.06 $1.95 Million - $3.35 Million
-92,854 Reduced 8.65%
980,939 $22 Million
Q2 2022

Aug 01, 2022
BUY
$17.78 - $42.39 $908,309 - $2.17 Million
51,086 Added 5.0%
1,073,793 $26.6 Million
Q1 2022

May 04, 2022
BUY
$29.67 - $60.28 $2 Million - $4.06 Million
67,395 Added 7.05%
1,022,707 $39.5 Million
Q4 2021

Feb 07, 2022
BUY
$47.84 - $64.34 $2.06 Million - $2.78 Million
43,132 Added 4.73%
955,312 $55.9 Million
Q3 2021

Nov 02, 2021
SELL
$59.27 - $95.73 $23.9 Million - $38.6 Million
-403,421 Reduced 30.66%
912,180 $54.1 Million
Q2 2021

Aug 03, 2021
SELL
$67.25 - $92.52 $762,884 - $1.05 Million
-11,344 Reduced 0.85%
1,315,601 $114 Million
Q1 2021

May 04, 2021
SELL
$72.16 - $117.4 $30.6 Million - $49.8 Million
-424,510 Reduced 24.24%
1,326,945 $109 Million
Q4 2020

Feb 01, 2021
SELL
$38.09 - $100.95 $26 Million - $68.9 Million
-682,968 Reduced 28.05%
1,751,455 $159 Million
Q3 2020

Nov 09, 2020
SELL
$30.41 - $40.5 $3.92 Million - $5.22 Million
-128,848 Reduced 5.03%
2,434,423 $97.3 Million
Q2 2020

Aug 07, 2020
SELL
$20.21 - $35.23 $18.4 Million - $32.1 Million
-911,097 Reduced 26.22%
2,563,271 $87.9 Million
Q1 2020

May 04, 2020
SELL
$17.28 - $31.88 $13 Million - $24.1 Million
-754,786 Reduced 17.85%
3,474,368 $77.2 Million
Q4 2019

Feb 06, 2020
BUY
$13.39 - $20.73 $10.7 Million - $16.6 Million
801,416 Added 23.38%
4,229,154 $82.8 Million
Q4 2019

Feb 04, 2020
SELL
$13.39 - $20.73 $3.07 Million - $4.76 Million
-229,582 Reduced 6.28%
3,427,738 $86.9 Million
Q3 2019

Nov 12, 2019
BUY
$15.47 - $22.5 $11.3 Million - $16.4 Million
729,390 Added 24.91%
3,657,320 $56.8 Million
Q2 2019

Aug 15, 2019
BUY
$15.61 - $20.44 $14.9 Million - $19.5 Million
953,756 Added 48.31%
2,927,930 $59.4 Million
Q1 2019

May 03, 2019
BUY
$13.15 - $18.71 $8.62 Million - $12.3 Million
655,314 Added 49.69%
1,974,174 $34.7 Million
Q4 2018

Feb 05, 2019
BUY
$11.48 - $16.98 $9.09 Million - $13.4 Million
791,540 Added 150.11%
1,318,860 $16.9 Million
Q3 2018

Nov 01, 2018
BUY
$8.75 - $16.29 $112,350 - $209,163
12,840 Added 2.5%
527,320 $8.59 Million
Q2 2018

Aug 02, 2018
SELL
$9.16 - $13.48 $553,355 - $814,326
-60,410 Reduced 10.51%
514,480 $5.83 Million
Q1 2018

May 04, 2018
BUY
$6.3 - $13.77 $1.51 Million - $3.31 Million
240,210 Added 71.77%
574,890 $5.61 Million
Q4 2017

Feb 01, 2018
BUY
$3.94 - $6.64 $953,046 - $1.61 Million
241,890 Added 260.69%
334,680 $2.05 Million
Q3 2017

Oct 27, 2017
BUY
$2.6 - $4.31 $241,254 - $399,924
92,790
92,790 $367,000

Others Institutions Holding FATE

# of Institutions
178
Shares Held
124M
Call Options Held
222K
Put Options Held
48.6K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $318M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email